Cargando…

The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study

D-dimer and prothrombin fragment (F1+2) levels are elevated in patients with peripheral artery disease (PAD). We examined their prognostic potential in predicting decreasing ABI and major adverse limb events (MALE). A total of 206 patients were recruited from St. Michael’s Hospital and followed for...

Descripción completa

Detalles Bibliográficos
Autores principales: Arfan, Sara, Zamzam, Abdelrahman, Syed, Muzammil H., Jain, Shubha, Jahanpour, Niousha, Abdin, Rawand, Qadura, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028031/
https://www.ncbi.nlm.nih.gov/pubmed/35453628
http://dx.doi.org/10.3390/biomedicines10040878
_version_ 1784691515550859264
author Arfan, Sara
Zamzam, Abdelrahman
Syed, Muzammil H.
Jain, Shubha
Jahanpour, Niousha
Abdin, Rawand
Qadura, Mohammad
author_facet Arfan, Sara
Zamzam, Abdelrahman
Syed, Muzammil H.
Jain, Shubha
Jahanpour, Niousha
Abdin, Rawand
Qadura, Mohammad
author_sort Arfan, Sara
collection PubMed
description D-dimer and prothrombin fragment (F1+2) levels are elevated in patients with peripheral artery disease (PAD). We examined their prognostic potential in predicting decreasing ABI and major adverse limb events (MALE). A total of 206 patients were recruited from St. Michael’s Hospital and followed for two years. Baseline plasma concentrations of D-dimer and F1+2 were recorded. Pearson’s correlation was used to assess the correlation between the biomarkers and ABI at year 2. During follow-up, multivariable Cox proportional hazard analysis was performed to investigate their role in predicting decreasing ABI (defined as change in ABI > −0.15) and MALE (defined as the need for arterial intervention or major limb amputation). Cumulative survival was assessed using Kaplan–Meier analysis. Baseline D-dimer and F1+2 levels were elevated in PAD patients (median (IQR) 1.34 (0.80–2.20) for D-dimer and 3.60 (2.30–4.74) for F1+2; p = 0.001) compared to non-PAD controls (median (IQR) 0.69 (0.29–1.20) for D-dimer and 1.84 (1.17–3.09) for F1+2; p = 0.001). Both markers were negatively correlated with ABI at year 2 (r = −0.231 for D-dimer, r = −0.49 for F1+2; p = 0.001). Cox analysis demonstrated F1+2 and D-dimer to be independent predictors of PAD status (HR = 1.27, 95% CI = 1.15–1.54; p = 0.013 for D-dimer and HR = 1.28, 95% CI = 1.14–1.58; p = 0.019 for F1+2). Elevated baseline concentrations of D-dimer and F1+2 were associated with high incidence of decreasing ABI and 1- and 2-year event-free survival (62% and 86%, respectively). Combined analysis of D-dimer and F1+2 provides important prognostic information that facilitates risk stratification for future disease progression and MALE outcomes in patients with PAD.
format Online
Article
Text
id pubmed-9028031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90280312022-04-23 The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study Arfan, Sara Zamzam, Abdelrahman Syed, Muzammil H. Jain, Shubha Jahanpour, Niousha Abdin, Rawand Qadura, Mohammad Biomedicines Article D-dimer and prothrombin fragment (F1+2) levels are elevated in patients with peripheral artery disease (PAD). We examined their prognostic potential in predicting decreasing ABI and major adverse limb events (MALE). A total of 206 patients were recruited from St. Michael’s Hospital and followed for two years. Baseline plasma concentrations of D-dimer and F1+2 were recorded. Pearson’s correlation was used to assess the correlation between the biomarkers and ABI at year 2. During follow-up, multivariable Cox proportional hazard analysis was performed to investigate their role in predicting decreasing ABI (defined as change in ABI > −0.15) and MALE (defined as the need for arterial intervention or major limb amputation). Cumulative survival was assessed using Kaplan–Meier analysis. Baseline D-dimer and F1+2 levels were elevated in PAD patients (median (IQR) 1.34 (0.80–2.20) for D-dimer and 3.60 (2.30–4.74) for F1+2; p = 0.001) compared to non-PAD controls (median (IQR) 0.69 (0.29–1.20) for D-dimer and 1.84 (1.17–3.09) for F1+2; p = 0.001). Both markers were negatively correlated with ABI at year 2 (r = −0.231 for D-dimer, r = −0.49 for F1+2; p = 0.001). Cox analysis demonstrated F1+2 and D-dimer to be independent predictors of PAD status (HR = 1.27, 95% CI = 1.15–1.54; p = 0.013 for D-dimer and HR = 1.28, 95% CI = 1.14–1.58; p = 0.019 for F1+2). Elevated baseline concentrations of D-dimer and F1+2 were associated with high incidence of decreasing ABI and 1- and 2-year event-free survival (62% and 86%, respectively). Combined analysis of D-dimer and F1+2 provides important prognostic information that facilitates risk stratification for future disease progression and MALE outcomes in patients with PAD. MDPI 2022-04-11 /pmc/articles/PMC9028031/ /pubmed/35453628 http://dx.doi.org/10.3390/biomedicines10040878 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arfan, Sara
Zamzam, Abdelrahman
Syed, Muzammil H.
Jain, Shubha
Jahanpour, Niousha
Abdin, Rawand
Qadura, Mohammad
The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
title The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
title_full The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
title_fullStr The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
title_full_unstemmed The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
title_short The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
title_sort clinical utility of d-dimer and prothrombin fragment (f1+2) for peripheral artery disease: a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028031/
https://www.ncbi.nlm.nih.gov/pubmed/35453628
http://dx.doi.org/10.3390/biomedicines10040878
work_keys_str_mv AT arfansara theclinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT zamzamabdelrahman theclinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT syedmuzammilh theclinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT jainshubha theclinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT jahanpourniousha theclinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT abdinrawand theclinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT qaduramohammad theclinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT arfansara clinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT zamzamabdelrahman clinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT syedmuzammilh clinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT jainshubha clinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT jahanpourniousha clinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT abdinrawand clinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy
AT qaduramohammad clinicalutilityofddimerandprothrombinfragmentf12forperipheralarterydiseaseaprospectivestudy